Sofie Biering-Sørensen1, Kristoffer Jarlov Jensen2, Susanne Havn Aamand3, Bastiaan Blok4, Andreas Andersen5, Ivan Monteiro6, Mihai G Netea4, Peter Aaby6, Christine Stabell Benn7, Kaare Robert Hasløv8. 1. Research Center for Vitamins & Vaccines (CVIVA), Bandim Health Project, Statens Serum Institut, DK-2300 Copenhagen S, Denmark; Projécto de Saúde Bandim, INDEPTH Network, Codex 1004, Bissau, Guinea-Bissau. Electronic address: s.biering@bandim.org. 2. Research Center for Vitamins & Vaccines (CVIVA), Bandim Health Project, Statens Serum Institut, DK-2300 Copenhagen S, Denmark; Projécto de Saúde Bandim, INDEPTH Network, Codex 1004, Bissau, Guinea-Bissau; Department of Cardiovascular and Renal Research, Faculty of Health Sciences, University of Southern Denmark, DK-5000 Odense, Denmark. 3. Bacterial Vaccine Department, Statens Serum Institut, DK-2300 Copenhagen S, Denmark. 4. Department of Internal Medicine, Radboud University Medical Center, 6525GA Nijmegen, The Netherlands. 5. Research Center for Vitamins & Vaccines (CVIVA), Bandim Health Project, Statens Serum Institut, DK-2300 Copenhagen S, Denmark; Projécto de Saúde Bandim, INDEPTH Network, Codex 1004, Bissau, Guinea-Bissau. 6. Projécto de Saúde Bandim, INDEPTH Network, Codex 1004, Bissau, Guinea-Bissau. 7. Research Center for Vitamins & Vaccines (CVIVA), Bandim Health Project, Statens Serum Institut, DK-2300 Copenhagen S, Denmark; Odense Patient Data Explorative Network, Institute of Clinical Research, University of Southern Denmark/Odense University Hospital, DK-5000 Odense C, Denmark. 8. Vaccine Quality Control, Statens Serum Institut, DK-2300 Copenhagen S, Denmark.
Abstract
INTRODUCTION:Bacille Calmette-Guérin (BCG) vaccine has beneficial non-specific effects on overall survival. After BCG vaccination, positive PPD response and scar formation are associated with increased survival. During a trial randomising low-birth-weight neonates to BCG at birth or the usual delayed BCG, the manufacturer of the BCG vaccine experienced a period with relatively slow growth rate of the BCG. We investigated the association between growth rate of BCG when manufacturing the vaccine and its capability to induce immune responses in vivo and in vitro. METHODS:1633 neonates were randomised to BCG at birth and examined for scar at 12 months; a subgroup was tested for PPD response at 2 and 6 months. The BCG batches from the Slow growth period were compared with the precedent and subsequent Normal growth batches with regard to prevalence and size of BCG scar and PPD response. We also tested the effect of batches on in vitro cytokine responses. RESULTS: At 12 months, the Slow growth batches were associated with higher BCG scar prevalence (98.2%) than the precedent batches (92.3%, p=0.01) but the prevalence remained high after return to normal growth (98.8%, p=0.52). The Slow growth batches were associated with larger scar size (5.0mm) than precedent (4.4mm, p<0.01) and subsequent batches (4.8mm, p=0.03). Compared with Normal growth batches, the Slow growth batches were associated with a higher prevalence of positive PPD responses, and among PPD positive children, a larger PPD reaction (geometric mean ratio: 1.40 (1.20-1.63)) at 2 months. In response to secondary heterologous stimulation, monocytes primed with Slow growth batches induced higher IL-6 (p=0.03) and TNF-α responses (p=0.03) compared with Normal growth batches. CONCLUSION: The study indicates that variations in the production of BCG vaccine may influence important immunological effects of the vaccine. TRIAL REGISTRATION: clinicaltrials.gov (NCT00625482).
RCT Entities:
INTRODUCTION: Bacille Calmette-Guérin (BCG) vaccine has beneficial non-specific effects on overall survival. After BCG vaccination, positive PPD response and scar formation are associated with increased survival. During a trial randomising low-birth-weight neonates to BCG at birth or the usual delayed BCG, the manufacturer of the BCG vaccine experienced a period with relatively slow growth rate of the BCG. We investigated the association between growth rate of BCG when manufacturing the vaccine and its capability to induce immune responses in vivo and in vitro. METHODS: 1633 neonates were randomised to BCG at birth and examined for scar at 12 months; a subgroup was tested for PPD response at 2 and 6 months. The BCG batches from the Slow growth period were compared with the precedent and subsequent Normal growth batches with regard to prevalence and size of BCG scar and PPD response. We also tested the effect of batches on in vitro cytokine responses. RESULTS: At 12 months, the Slow growth batches were associated with higher BCG scar prevalence (98.2%) than the precedent batches (92.3%, p=0.01) but the prevalence remained high after return to normal growth (98.8%, p=0.52). The Slow growth batches were associated with larger scar size (5.0mm) than precedent (4.4mm, p<0.01) and subsequent batches (4.8mm, p=0.03). Compared with Normal growth batches, the Slow growth batches were associated with a higher prevalence of positive PPD responses, and among PPD positive children, a larger PPD reaction (geometric mean ratio: 1.40 (1.20-1.63)) at 2 months. In response to secondary heterologous stimulation, monocytes primed with Slow growth batches induced higher IL-6 (p=0.03) and TNF-α responses (p=0.03) compared with Normal growth batches. CONCLUSION: The study indicates that variations in the production of BCG vaccine may influence important immunological effects of the vaccine. TRIAL REGISTRATION: clinicaltrials.gov (NCT00625482).
Authors: T N Nissen; N M Birk; B A Blok; R J W Arts; A Andersen; J Kjærgaard; L M Thøstesen; T Hoffmann; D L Jeppesen; S D Nielsen; P-E Kofoed; L G Stensballe; P Aaby; M Ruhwald; M G Netea; C S Benn; O Pryds Journal: Eur J Clin Microbiol Infect Dis Date: 2017-09-10 Impact factor: 3.267
Authors: Emma Rey-Jurado; Felipe Tapia; Natalia Muñoz-Durango; Margarita K Lay; Leandro J Carreño; Claudia A Riedel; Susan M Bueno; Yvonne Genzel; Alexis M Kalergis Journal: Front Immunol Date: 2018-01-18 Impact factor: 7.561
Authors: Asimenia Angelidou; Maria-Giulia Conti; Joann Diray-Arce; Christine S Benn; Frank Shann; Mihai G Netea; Mark Liu; Lakshmi Prasad Potluri; Guzman Sanchez-Schmitz; Robert Husson; Al Ozonoff; Beate Kampmann; Simon Daniël van Haren; Ofer Levy Journal: Vaccine Date: 2020-01-28 Impact factor: 4.169
Authors: Frederik Schaltz-Buchholzer; Mike Berendsen; Adam Roth; Kristoffer Jarlov Jensen; Morten Bjerregaard-Andersen; Marcus Kjær Sørensen; Ivan Monteiro; Peter Aaby; Christine Stabell Benn Journal: BMJ Glob Health Date: 2020-09